Peter J. Ell spends much of his time researching Nuclear medicine, Positron emission tomography, Radiology, Internal medicine and Tomography. His studies in Nuclear medicine integrate themes in fields like Coronary artery disease, Cancer, Magnetic resonance imaging and Perfusion. His work on Fluorodeoxyglucose as part of general Positron emission tomography study is frequently connected to Vital capacity, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.
His Radiology research incorporates themes from Clinical Oncology, Colorectal cancer and Carcinoma. Peter J. Ell has researched Internal medicine in several fields, including Endocrinology and Cardiology. The study incorporates disciplines such as Carcinoid tumors and Fdg pet ct in addition to Tomography.
Peter J. Ell mostly deals with Nuclear medicine, Internal medicine, Radiology, Positron emission tomography and Cardiology. His biological study spans a wide range of topics, including Cerebral blood flow, Tomography, Ejection fraction and Perfusion. His study focuses on the intersection of Internal medicine and fields such as Endocrinology with connections in the field of Receptor.
His Radiology study combines topics from a wide range of disciplines, such as Cancer and Carcinoma. His study in Positron emission tomography focuses on Fluorodeoxyglucose in particular. His Dopamine receptor D2 study also includes
His primary scientific interests are in Nuclear medicine, Radiology, Positron emission tomography, Internal medicine and PET-CT. When carried out as part of a general Nuclear medicine research project, his work on Standardized uptake value is frequently linked to work in In patient, therefore connecting diverse disciplines of study. Many of his studies on Radiology involve topics that are commonly interrelated, such as Carcinoma.
His Positron emission tomography research incorporates elements of Breast cancer, Prospective cohort study and Computed tomography. His Internal medicine research includes themes of Endocrinology, Oncology and Cardiology. His PET-CT research is multidisciplinary, incorporating perspectives in Neuroendocrine tumors and Abdominal aortic aneurysm, Aneurysm.
Peter J. Ell mostly deals with Nuclear medicine, Positron emission tomography, Radiology, PET-CT and Internal medicine. His work on Fdg pet ct as part of his general Nuclear medicine study is frequently connected to Solid-state, thereby bridging the divide between different branches of science. His Positron emission tomography research is multidisciplinary, incorporating elements of Temporal lobe, Epilepsy surgery and Epilepsy.
His work on Tomography, 18f fdg pet and Standardized uptake value as part of general Radiology study is frequently linked to Vital capacity, therefore connecting diverse disciplines of science. His PET-CT research is multidisciplinary, relying on both Clinical significance, Neuroendocrine tumors, Intermediate Grade, Lung cancer and Histology. The Internal medicine study combines topics in areas such as Endocrinology and Verbal learning.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Randomized Multicenter Trial of Sentinel Node Biopsy Versus Standard Axillary Treatment in Operable Breast Cancer: The ALMANAC Trial
Robert Edward Mansel;Lesley Fallowfield;Mark Kissin;Amit Goyal.
Journal of the National Cancer Institute (2006)
Delivering affordable cancer care in high-income countries
Richard Sullivan;Jeffrey Peppercorn;Karol Sikora;John Zalcberg.
Lancet Oncology (2011)
Recognition of mental state terms. Clinical findings in children with autism and a functional neuroimaging study of normal adults.
Simon Baron-Cohen;Howard Ring;John Moriarty;Bettina Schmitz.
British Journal of Psychiatry (1994)
Myocardial perfusion scintigraphy: the evidence
S. R. Underwood;C. Anagnostopoulos;M. Cerqueira;P. J. Ell.
European Journal of Nuclear Medicine and Molecular Imaging (2004)
Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial.
A N Serafini;S J Houston;I Resche;D P Quick.
Journal of Clinical Oncology (1998)
Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG
Irfan Kayani;Jamshed B. Bomanji;Ashley Groves;Gerard Conway.
Cancer (2008)
Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer.
Oliver Sartor;Robert H Reid;Peter J Hoskin;Donald P Quick.
Urology (2004)
Exenatide and the treatment of patients with Parkinson’s disease
Iciar Aviles-Olmos;John Dickson;Zinovia Kefalopoulou;Atbin Djamshidian.
Journal of Clinical Investigation (2013)
Clinical role of positron emission tomography in oncology.
JB Bomanji;DC Costa;PJ Ell.
Lancet Oncology (2001)
A dose-controlled study of 153Sm-Ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastase
I. Resche;J.-F. Chatal;A. Pecking;P. Ell.
European Journal of Cancer (1997)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Ottawa Hospital
University of Cambridge
University College London
Medical University of South Carolina
National Institutes of Health
Brighton and Sussex Medical School
University of Aberdeen
University College London
King's College London
University College London
Columbia University
Virginia Commonwealth University
University of California, Irvine
Fudan University
University of Shizuoka
Hanyang University
Emory University
Aarhus University
Yale University
University of California, Los Angeles
Baylor College of Medicine
University of Chicago
National Institute of Water and Atmospheric Research
University of Reading
Arizona State University